Maintenance Notice (4:00 AM - 1:30 PM January 5, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | New tool "TCI SpectraViewer" | [Product Highlights] o-Nitrobenzyl Photolabile... | Product Document Searching Made Easy by 2D Code!
Maximum quantity allowed is 999
CAS RN: 231277-92-2 | Product Number: L0360
Lapatinib
Purity: >98.0%(T)(HPLC)
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
- N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
Size | Unit Price | Hyderabad | Japan* | Quantity |
---|---|---|---|---|
250MG |
₹4,800.00
|
2 | 5 |
|
1G |
₹5,200.00
|
Contact Us | ≥40 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | L0360 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__2__9H__2__6ClFN__4O__4S = 581.06 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Store Under Inert Gas | Store under inert gas |
Condition to Avoid | Air Sensitive,Heat Sensitive |
Packaging and Container | 250MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 231277-92-2 |
Reaxys Registry Number | 10502247 |
PubChem Substance ID | 468592164 |
MDL Number | MFCD09264194 |
Appearance | White to Light yellow powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Volumetric Analysis) | min. 98.0 % |
Melting point | 145.0 to 149.0 °C |
NMR | confirm to structure |
Melting Point | 147 °C |
Maximum Absorption Wavelength | 367(MeOH) nm |
Hazard Statements | H362 : May cause harm to breast-fed children. H413 : May cause long lasting harmful effects to aquatic life. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
RTECS# | VA0952500 |
References
- Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases (a review)
- Molecular predictors of response to trastuzumab and lapatinib in breast cancer (a review)
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.